Plain-English translation of NCT07137832 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether intra-arterial thrombolysis—a clot-dissolving treatment delivered directly into blocked blood vessels—improves recovery when combined with standard endovascular treatment (a minimally invasive procedure to remove clots). The trial will follow 530 people who have had a stroke caused by a medium-sized vessel blockage and compare those who receive this medication alongside standard care to those who receive standard care alone.
Many stroke patients with medium-sized vessel blockages have poor outcomes even after standard clot-removal procedures. Doctors hope that adding this clot-dissolving treatment will help restore blood flow more effectively and help more patients recover with better long-term function.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of two groups. One group will receive the clot-dissolving treatment delivered directly into the blocked blood vessel, along with standard stroke care; the other group will receive standard care alone. The research team will follow your recovery and assess your functional outcome at 90 days after your stroke using standardized measures.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China